崔勇①, 张荣香②, 王福立③, 魏本尊④, 张建东⑤. 新辅助化疗联合术后同步放化疗治疗Ⅲ期胃癌的疗效分析*[J]. 中国肿瘤临床, 2016, 43(17): 747-752. DOI: 10.3969/j.issn.1000-8179.2016.17.389
引用本文: 崔勇①, 张荣香②, 王福立③, 魏本尊④, 张建东⑤. 新辅助化疗联合术后同步放化疗治疗Ⅲ期胃癌的疗效分析*[J]. 中国肿瘤临床, 2016, 43(17): 747-752. DOI: 10.3969/j.issn.1000-8179.2016.17.389
shu
Yong CUI1, Rongxiang ZHANG2, Fuli WANG3, Benzun WEI4, Jiandong ZHANG5. Efficacy of neoadjuvant chemotherapy combined with postoperative adjuvant concurrent radiotherapy and chemotherapy for stage Ⅲadvanced gastric cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(17): 747-752. DOI: 10.3969/j.issn.1000-8179.2016.17.389
Citation: Yong CUI1, Rongxiang ZHANG2, Fuli WANG3, Benzun WEI4, Jiandong ZHANG5. Efficacy of neoadjuvant chemotherapy combined with postoperative adjuvant concurrent radiotherapy and chemotherapy for stage Ⅲadvanced gastric cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(17): 747-752. DOI: 10.3969/j.issn.1000-8179.2016.17.389
shu

新辅助化疗联合术后同步放化疗治疗Ⅲ期胃癌的疗效分析*

Efficacy of neoadjuvant chemotherapy combined with postoperative adjuvant concurrent radiotherapy and chemotherapy for stage Ⅲadvanced gastric cancer

    摘要
  • 摘要: 目的：探讨XELOX（奥沙利铂+ 卡培他滨）方案新辅助化疗联合术后同步放化疗治疗Ⅲ期进展期胃癌的临床疗效。方法：选取寿光市人民医院、淄博市中心医院和山东大学附属千佛山医院自2010年1 月至2013年1 月收治的Ⅲ期进展期胃癌患者55例，随机分为治疗组（28例）和对照组（27例）。 治疗组给予XELOX方案新辅助化疗，然后行手术，术后给予三维适形放疗同步XELOX方案化疗；对照组先行手术，术后给予同步放化疗。结果：治疗组新辅助化疗后客观有效率为75% 。治疗组肿瘤切除率为
    92.9% ，明显高于对照组的81.5%（P = 0.049）。 治疗组肿瘤根治性切除率为71.4% ，明显高于对照组的44.4%（P = 0.043）。 治疗组淋巴结转移率为48.2% ，明显低于对照组的60.2%（P = 0.006）。 治疗组有1 例患者术后病理肿瘤完全消退，9 例消退良好，7 例中度消退。治疗组和对照组的1、2、3 年生存率分别为88.9% vs . 69.2% 、66.7% vs . 46.2% 、59.3% vs . 38.5% ，两组比较差异均具有统计学意义（P = 0.037、P = 0.045、P = 0.049）。 两组不良反应发生率比较差异无统计学意义（P > 0.05）。 结论：XELOX方案新辅助化疗联合术后同步放化疗可以提高Ⅲ期进展期胃癌患者的肿瘤根治性切除率和术后远期生存率，降低淋巴结转移率。

     

    Abstract: Objective:To investigate the clinical efficacy of neoadjuvant chemotherapy with XELOX (oxaliplatin+capecitabine) regimen combined with postoperative adjuvant concurrent radiotherapy and chemotherapy for stage III advanced gastric cancer. Methods:A total of 55patients with stage III advanced gastric cancer from Shouguang People's Hospital, Zibo Central Hospital, and Shandong Qian-foshan Hospital of Shandong University were enrolled in this study. The patients were randomly divided into the treatment group and the control group. In the treatment group, 28patients were treated with neoadjuvant chemotherapy with XELOX regimen, underwent surgery, and then received postoperative adjuvant three-dimensional conformal radiotherapy synchronous XELOX regimen. In the con -trol group, 27cases underwent surgery in advance, and received radiotherapy synchronous XELOX regimen. Results:The objective re -sponse rate of the treatment group was 75%. The tumor resection rate was92. 9%, which was significantly higher than that of the con -trol group at 81. 5% (P=0. 049 ). The tumor radical resection rates in the treatment and control groups were 71. 4% and 44. 4%, respec -tively, which are significantly different ( P=0. 043 ). The lymph node metastasis in the treatment group was 48. 2%, which was significant -ly lower than that of the control group at 60. 2% (P=0. 006 ). In the treatment group, one case achieved pathologic complete tumor re -gression, 9 cases were of good tumor regression, and 7 cases were of moderate tumor regression. The 1-year, 2-year, and 3-year surviv -al rates of the treatment and control groups were 88. 9% vs . 69. 2%,66. 7% vs . 46. 2%, and 59. 3% vs . 38. 5%, respectively, which are sig -nificantly different(P=0. 037 , P=0. 045 , and P=0. 049 ). The results showed no significant difference of incidence of toxicity in the two groups ( P>0. 05). Conclusion: Neoadjuvant chemotherapy with XELOX regimen combined with postoperative adjuvant concurrent chemoradiotherapy for stage III advanced gastric cancer can improve the radical resection rate and long- term postoperative survival rate of patients, as well as reduce the rate of lymph node metastasis.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回